NovoCure Ltd.

215 articles with NovoCure Ltd.

• Novocure to Participate in the Jefferies 2019 Global Healthcare Conference

  5/24/2019

  Novocure announced that Bill Doyle, Novocure’s Executive Chairman, will participate in the Jefferies 2019 Global Healthcare Conference on June 4, 2019, in New York City.

• 

  Novocure Wins FDA Approval for First Mesothelioma Treatment in 15 Years

  5/24/2019

  Shares of NovoCure are up more than 6% in premarket trading after the company announced it won regulatory approval for its mesothelioma treatment, NovoTTF-100L System.

• FDA Approves the NovoTTF-100LTM System in Combination with Chemotherapy for the Treatment of Malignant Pleural Mesothelioma

  5/23/2019

  Novocure (NASDAQ: NVCR) today announced that the U.S. Food and Drug Administration (FDA) has approved the NovoTTF-100L System in combination with pemetrexed plus platinum-based chemotherapy for the first-line treatment of unresectable, locally advanced or metastatic, malignant pleural mesothelioma (MPM). NovoTTF-100L is a non-invasive, antimitotic cancer treatment that delivers Tumor Treating Fields to the region of the tumor.

• Medicare Issues Proposed Local Coverage Determination that Provides Coverage of Optune® for Newly Diagnosed Glioblastoma

  5/10/2019

  Novocure (NASDAQ: NVCR) today announced the Medicare durable medical equipment (DME) Medicare Administrative Contractors (MACs) have issued a proposed local coverage determination (LCD) that provides coverage of Tumor Treating Fields, or Optune, for newly diagnosed glioblastoma (GBM)

• Novocure Reports First Quarter 2019 Financial Results and Provides Company Update

  5/2/2019

  Quarterly net revenues of $73.3 million, representing 41 percent growth versus the first quarter 2018 and 5 percent growth versus the fourth quarter 2018

• Novocure Announces the International Journal of Radiation Oncology, Biology, Physics Publishes Data Demonstrating Higher Doses of Tumor Treating Fields Improved Survival of Newly Diagnosed Glioblastoma Patients

  4/30/2019

  The study provides a definition for Tumor Treating Fields dose and sets a framework for future work on Tumor Treating Fields dosimetry and treatment planning

• Novocure Publishes 2018 Annual Report Featuring Company’s Vision, Mission and Values

  4/15/2019

  Novocure’s mission and values support its overarching patient-forward vision to make a difference in cancer

• Inaugural AACR-Novocure Tumor Treating Fields Research Grant Recipients Announced at AACR Annual Meeting 2019

  4/3/2019

  The recipients of the AACR-Novocure Tumor Treating Fields research grants were announced on April 2 at the American Association for Cancer Research Annual Meeting 2019 in Atlanta.

• Novocure to Report First Quarter 2019 Financial Results

  4/2/2019

  Novocure announced that it will report financial results for the first quarter 2019 on Thursday, May 2, 2019, before the U.S. financial markets open.

• Novocure Initiates Phase 3 Pivotal Trial in Recurrent Ovarian Cancer

  3/22/2019

  INNOVATE-3 will test the efficacy of Tumor Treating Fields combined with paclitaxel in patients with recurrent, platinum-resistant ovarian cancer

• 

  BioSpace Movers and Shakers: March 22

  3/22/2019

  Biotech and pharma companies make appointments to strengthen executive teams, with moves at Sanofi, Forma, Orchard, CLSA, Sangamo, and more.

• Novocure’s Chief Science Officer Retires after 17 Years of Service

  3/21/2019

  Novocure (NASDAQ: NVCR) today announced the retirement of Dr. Eilon Kirson, Novocure’s Chief Science Officer and Head of Research and Development, effective May 1, 2019.

• Novocure Announces 48 Presentations and a Symposium Session on Tumor Treating Fields at the American Association for Cancer Research Annual Meeting 2019

  3/21/2019

  A special symposium session, intended to highlight therapeutic advances, will focus on Tumor Treating Fields as a fourth modality in cancer treatment

• Novocure to Participate in Oppenheimer’s 29th Annual Healthcare Conference

  3/18/2019

  Novocure announced that Wilco Groenhuysen, Novocure’s Chief Financial Officer, will participate in Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019, in New York City.

• Novocure Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Company Update

  2/28/2019

  Three additional phase 3 clinical trials ongoing studying the use of Optune in brain metastases, non-small-cell lung cancer and pancreatic cancer

• Novocure Announces Fourth Quarter and Full Year 2018 Operating Statistics, Preliminary Net Revenues and Provides Company Update

  1/7/2019

  Full year 2018 preliminary net revenues of $248.0 million, representing annual growth of more than 40 percent compared to 2017

• Novocure to Participate in the 37th Annual J.P. Morgan Healthcare Conference

  12/21/2018

  Novocure (NASDAQ: NVCR) will participate in the 37th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 9, 2019, in San Francisco.

• Novocure and the AACR Announce Four Inaugural Research Grants to Promote and Support Innovative Research on Tumor Treating Fields

  12/17/2018

  The grants represent a joint effort to promote and support innovative research on Tumor Treating Fields.

• Sub-Group Analysis of Novocure’s EF-14 Phase 3 Pivotal Trial in Newly Diagnosed Glioblastoma Published in Journal of Neuro-Oncology Demonstrating More Time on Optune® Predicted Increased Survival

  12/6/2018

  Novocure (NASDAQ:NVCR) announced today that the results of a retrospective post-hoc sub-group analysis of its EF-14 phase 3 pivotal trial in newly diagnosed glioblastoma (GBM) have been published in the Journal of Neuro-Oncology.

• Novocure and Zai Lab Awarded Deal of the Year at 5th Annual BioCentury China Healthcare Summit in Shanghai, China

  11/14/2018

  Novocure announced today that Novocure and Zai Lab have received the Deal of the Year Award from BayHelix at a ceremony during the 5th annual BioCentury China Healthcare Summit in Shanghai, China